Literature DB >> 24819880

Neuropharmacology of memory consolidation and reconsolidation: Insights on central cholinergic mechanisms.

M G Blake1, M C Krawczyk1, C M Baratti1, M M Boccia2.   

Abstract

Central cholinergic system is critically involved in all known memory processes. Endogenous acetylcholine release by cholinergic neurons is necessary for modulation of acquisition, encoding, consolidation, reconsolidation, extinction, retrieval and expression. Experiments from our laboratory are mainly focused on elucidating the mechanisms by which acetylcholine modulates memory processes. Blockade of hippocampal alpha-7-nicotinic receptors (α7-nAChRs) with the antagonist methyllycaconitine impairs memory reconsolidation. However, the administration of a α7-nAChR agonist (choline) produce a paradoxical modulation, causing memory enhancement in mice trained with a weak footshock, but memory impairment in animals trained with a strong footshock. All these effects are long-lasting, and depend on the age of the memory trace. This review summarizes and discusses some of our recent findings, particularly regarding the involvement of α7-nAChRs on memory reconsolidation.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acetylcholine; Alpha7 nicotinic receptors; Choline; Hippocampus; Inhibitory avoidance; Memory; Memory consolidation; Memory reconsolidation; Methyllycaconitine; Mice

Mesh:

Substances:

Year:  2014        PMID: 24819880     DOI: 10.1016/j.jphysparis.2014.04.005

Source DB:  PubMed          Journal:  J Physiol Paris        ISSN: 0928-4257


  16 in total

Review 1.  Nociceptin and the nociceptin receptor in learning and memory.

Authors:  Raül Andero
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-02-24       Impact factor: 5.067

2.  Neuroprotective effect of ipriflavone against scopolamine-induced memory impairment in rats.

Authors:  Hani S Hafez; Doaa A Ghareeb; Samar R Saleh; Mariam M Abady; Maha A El Demellawy; Hend Hussien; Nihad Abdel-Monem
Journal:  Psychopharmacology (Berl)       Date:  2017-07-22       Impact factor: 4.530

3.  Augmentation of Exposure Therapy With Cholinergic Blockade: Promising Novel Approach or Too Early to Tell?

Authors:  Barbara O Rothbaum; Kerry J Ressler
Journal:  Biol Psychiatry       Date:  2019-11-01       Impact factor: 13.382

4.  Huperzine A inhibits immediate addictive behavior but not behavioral sensitization following repeated morphine administration in rats.

Authors:  Jinling Sun; Lin Tian; Ruisi Cui; Xinwang Li
Journal:  Exp Ther Med       Date:  2017-02-02       Impact factor: 2.447

Review 5.  The effect of α7 nicotinic receptor activation on glutamatergic transmission in the hippocampus.

Authors:  Qing Cheng; Jerrel L Yakel
Journal:  Biochem Pharmacol       Date:  2015-07-23       Impact factor: 5.858

6.  DADS Analogues Ameliorated the Cognitive Impairments of Alzheimer-Like Rat Model Induced by Scopolamine.

Authors:  Apra Manral; Poonam Meena; Vikas Saini; Fouzia Siraj; Shruti Shalini; Manisha Tiwari
Journal:  Neurotox Res       Date:  2016-05-05       Impact factor: 3.911

Review 7.  Going with the grain: Fiber, cognition, and the microbiota-gut-brain-axis.

Authors:  Kirsten Berding; Carina Carbia; John F Cryan
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-28

8.  T cell immunity to glatiramer acetate ameliorates cognitive deficits induced by chronic cerebral hypoperfusion by modulating the microenvironment.

Authors:  Li Chen; Yang Yao; Changjuan Wei; Yanan Sun; Xiaofeng Ma; Rongxin Zhang; Xiaolin Xu; Junwei Hao
Journal:  Sci Rep       Date:  2015-09-22       Impact factor: 4.379

Review 9.  Acetylcholine release and inhibitory interneuron activity in hippocampal CA1.

Authors:  A Rory McQuiston
Journal:  Front Synaptic Neurosci       Date:  2014-09-16

10.  Effects of imperatorin on scopolamine-induced cognitive impairment and oxidative stress in mice.

Authors:  Barbara Budzynska; Anna Boguszewska-Czubara; Marta Kruk-Slomka; Krystyna Skalicka-Wozniak; Agnieszka Michalak; Irena Musik; Grazyna Biala
Journal:  Psychopharmacology (Berl)       Date:  2014-09-05       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.